Loading clinical trials...
Loading clinical trials...
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfuncti...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Actelion
NCT07333183 · Pulmonary Hypertension, Interstitial Lung Disease (ILD), and more
NCT05746039 · Obesity, Interstitial Lung Disease, and more
NCT07537517 · Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH), and more
NCT06770023 · Lung Transplant, Pulmonary Hypertension
NCT03854071 · Heart Failure, Pulmonary Hypertension, and more
Kentuckiana Pulmonary Associates
Louisville, Kentucky
Boston University School of Medicine
Boston, Massachusetts
University of Michigan Internal Medicine Cardiology, Pulmonary Hypertension Program
Ann Arbor, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions